Des Moines, Iowa 50309 Phone: (515) 657-7138



InnoVenture Iowa, LLC

Investment Committee Meeting Wednesday, July 12, 2023 6:00 am

Public Webinar Access:

https://us02web.zoom.us/i/87523655985?pwd=RXJ5bWtNd2qrQilhNndFRXhqbiViQT09

I. Committee Chair Dan Cosgrove

A. Welcome

B. Roll Call Action

C. Approval of June 28 Meeting Minutes Action

II. Public Comment Period

A public comment period for the full meeting will be held at this time to accommodate visitors. This period is limited to 10 minutes.

Closed Session [lowa Code sections 15.118, 21.5(1)a and 22.7]**

Discussion of Information Contained in Startup Due Diligence Process

IV. Investment Briefs Kaylee Williams

- A. Mid-Year Review
- B. Cash Position (Deployed Capital)
- C. Pipeline Discussion: Risks & Merits

Discussion

D. ClinicNote

Discussion

Open Session [lowa Code sections 15.118, 21.5(1)a and 22.7]**

Reopen Meeting for Formal Adjournment

VII. Vote Action

VII. Adjourn Action

Investment Committee Members:

Martina Bockenstedt, Shane Larson, Anita Norian, Leigh Parker, Dan Cosgrove

Non-Voting Attendees:

Kaylee Williams - Investment Director, Steve Brody - CEO, BioConnect Iowa

INNOVENTURE IOWA, LLC 666 Walnut Street, Suite 1285 Des Moines, Iowa 50309

Phone: (515) 657-7138



Please Note:

The meeting will convene no earlier than stated above, but may begin later, depending on the length of earlier meetings. Agenda items may be considered out of order at the discretion of the Chair for each meeting. If you require accommodation to participate in this public meeting, call (515) 657-7138 to make your request. Please notify us as soon as possible in advance of the meeting.

**The InnoVenture Iowa Investment Committee, if a quorum is present, may go into closed session pursuant to Iowa Code sections 21.5(1)a, 15.118, 22.7.3, 22.7.6 and 22.7.8 to review and discuss records InnoVenture Iowa is required to treat as confidential under Iowa Iaw. This includes confidential business and financial information about applicants and industrial prospects with which the Fund is currently negotiating.